DOCSLIB.ORG

Trigeminal Neuropathy with Nasal Ulceration: Report of Two Cases and One Necropsy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trigeminal Neuropathy with Nasal Ulceration: Report of Two Cases and One Necropsy J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.105 on 1 February 1976. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry, 1976, 39, 105-113 Trigeminal neuropathy with nasal ulceration: report of two cases and one necropsy J. D. SPILLANE AND H. URICH From the Department of Neurology, University Hospital of Wales, Cardiff, and the Institute ofPathology, The London Hospital, London SYN OP SI s Two cases are reported of progressive trigeminal neuropathy with nasal ulceration. One patient developed signs of spinal cord involvement 15 years after the onset of trigeminal symptoms and died after a total course of 21 years. Necropsy revealed an unusual trigeminospinal system degeneration with deposition of amyloid-like substances in the affected structures. The other patient is alive eight years after the onset of symptoms, the only indication of a lesion outside the trigeminal nerve being a patch of numbness in one leg. guest. Protected by copyright. In a previous paper on isolated trigeminal reflexes were absent and the sensations of touch, neuropathy (Spillane and Wells, 1959) one of us pain, and temperature were impaired in the first and described a patient with total bilateral trigeminal second divisions on both sides, loss being absolute loss accompanied by progressive ulceration of for all modalities on the left side. There were slighter changes in both third divisions. Deep pressure and her nose (case 15). We now wish to report the vibration sense were normal. Taste was absent in the subsequent evolution of her condition and post- anterior two-thirds of the tongue. She could not mortem findings which we believe to be unique. appreciate the temperature of food on the left side We also wish to record another patient who dis- played similar symptoms and signs, at least in the early stages of her disease. CASE 1 CLINICAL HISTORY A widow, aged 59 years, was first seen in 1950. Her illness began in 1949 with redness and pain of both eyes. She attended an ophthalmic clinic where a diagnosis of bilateral keratocon- junctivitis (Sjogren's disease) was made. A few http://jnnp.bmj.com/ months later a red, tender, and painful sore appeared at the edge of her left nostril. Biopsy in 1950 showed a hyperkeratotic lesion with superficial inflammation but no evidence of neoplasm. The sore increased in size and the outer margin of the nostril was pro- gressively eroded. In January 1951 both sides of her forehead became numb; six months later her left upper lip was numb. Thereafter, numbness spread on September 29, 2021 by rapidly over the whole of the left side of her face and in August 1951 over the right side of her face. Her mouth and tongue became dry. In October 1951 there was bilateral keratoconjunctivitis with small irregular pupils and bilateral corneal opacities. Her ( i 1t-1 left nostril was ulcerated (Fig. la and b). The corneal FIG. 1 Case 1. Two years after onset; erosioni of (Accepted 19 August 1975.) left ala nasi, bilateralptosis, anrd neuropathic keratitis. 105 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.105 on 1 February 1976. Downloaded from 106 J. D. Spillane and H. Urich of her mouth. There was no involveement of the no contraction of masticatory muscles could be motor root of either trigeminal nervie. There was palpated. There was almost total bilateral trigeminal no symptom or sign of involvement elsewhere in the anaesthesia. Hearing remained normal, speech nervous system and investigations iwere entirely intelligible. By the mid-'60s she was becoming un- negative. No evidence of syphilis, sarcoidosis, steady on her feet and she often stumbled and fell. systemic lupus, or scleroderma emerged. Sphincter functions were not affected. She com- Over the years her condition stead]ily worsened. plained that her legs were cold and she often By 1957 her nose was totally eroded (Fig. 2a and b), wrapped them in a shawl and retired to bed. The she was profoundly anaemic and siie lost much lower limbs were very thin but arterial pulsations at weight. Eyesight was grossly impaired because of the ankles were normal. Knee and ankle jerks were corneal opacities, she chewed and swtallowed with gradually reduced and subsequently lost. Extensor plantar reflexes were first detected in 1965 and remained until her death five years later. No sensory abnormality was found in her lower limbs until 1966 when posture and vibration could not be appreci- ated in her feet. Subsequently, vibration could not be appreciated below the knees. Superficial sensation was impaired only distally and never profoundly. In her upper limbs, superficial sensation did not seem to be impaired, although grips were weak and hands clumsy. There was postural and vibration loss in the t hands; the arm reflexes were never lost. She remainedguest. Protected by copyright. able to feed herself with difficulty until her terminal illness. She was alert and orientated until the end. / Thus, this strange neurological illness began in the trigeminal sensory system and some 15 years later §S involved the spinal cord. There were no clues to its nature. ...... NECROPSY FINDINGS (West Cardiff Area Laboratory :-, x P.M. 213/70) There were no significant abnormali- ties outside the nervous system. In particular there was no evidence of generalized amyloidosis, multiple FIG. 2 Case 1. Six years later; total destruction of myeloma, systemic lupus erythematosus, or any nose, bilateral trigeminal anaesthesia. other multisystemic disease. EXAMINATION OF NERVOUS SYSTEM (L.H. P.M. 4/A/71) The macroscopic appearances of the brain difficulty, and had no sense of taste. Nevertheless, were unremarkable. Transverse sections through the alert and spinal cord showed symmetrical greyish discolora- she remained uncomplaining; repeated http://jnnp.bmj.com/ neurological examinations were otherwise negative. tion in the posterior parts of the lateral columns and There was still no sign of involvement of the motor in the posterior columns, particularly the fasciculus roots of the trigeminal nerves but the sensory loss gracilis. had progressed. She could scarcely detect the presence of food in her mouth. Sensory loss was MICROSCOPIC APPEARANCES The lesions were con- more or less complete in both first and second fined to the trigeminal nerve and its pathways, and divisions of the trigeminal nerves; it was impaired to the long tracts of the spinal cord. sensation was in both third divisions. Deep impaired. on September 29, 2021 by There was bilateral ptosis, small pupils, and loss of SENSORY ROOT OF TRIGEMINAL NERVE The entire secretions from lacrimal and salivary glands. She root from its entry into the pons to the proximity of retained a very feeble sense of smell. the Gasserian ganglion was severely affected. The From 1958 onwards, until her death in 1970 from glial part of the root was devoid of axons and myelin bronchopneumonia at the age of 78 years, she re- sheaths and showed astrocytic proliferation with fused hospital admission and neurological examina- fibrillary gliosis. Distal to the glio-Schwannian tions had to be made in her home. In the 1960s she junction, the root was infiltrated by an abnormal became very thin, her jaw movements were weak and substance, consisting of two components, A and B, J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.105 on 1 February 1976. Downloaded from Trigeminal neuropathy with nasal ulceration: report of two cases and one necropsy 107 TABLE STAINING REACTIONS OF INFILTRATING SUBSTANCES Method Substance Control (sporadic amyloid neuropathy) A B Congo red+ polarized light Weakly positive birefringent, Negative Strongly to weakly positive dichroic, polarization colour birefringent, dichroic, green polarization colour green Sirius red+ polarized light Positive birefringent, dichroic, Negative Positive birefringent, dichroic polarization colour green polarization colour green Wolman's toluidine blue + polarized Purplish blue birefringent, Blue Purplish blue birefringent, light dichroic, polarization colour dichroic, polarization colour red red Crystal violet Gamma metachromasia (red) Beta metachromasia Gamma metachromasia (red) (purple) Lendrum's sodium sulphate-alcian Green Khaki Green blue-van Gieson Thioflavin T Greenish fluorescence Greenish fluorescence Greenish fluorescence Luxol-fast blue-cresyl violet Light blue Dark blue Light blue guest. Protected by copyright. 'S -- ->f>...... ' .Ej . Kap1'-. -t .,jU S . S . FIG. 3 Case 1. Trigeminal root; infiltration ofglio-Schwannian junction by amyloid-like material. Lighter component represents substance A, darker substance B. Crystal violet, x 90. http://jnnp.bmj.com/ on September 29, 2021 by with different staining reactions (Table). Substance beading in places (Fig. 4). The infiltration stopped A was abundant at the junction, gradually giving short of the entry of the sensory root into the way to infiltration with substance B (Fig. 3). trigeminal ganglion where some deposits of substance Throughout its length, the root was devoid of axons A again became apparent. Throughout the length of and myelin sheaths, the individual fibres being the root the walls of blood vessels were infiltrated infiltrated with substance B. This formed solid or with substance B. tubular strands varying in thickness, with a some- what irregular outline and a tendency to coarse GASSERIAN GANGLION The neurones of the trig- J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.105 on 1 February 1976. Downloaded from 108 J. D. Spillane and H. Urich -%';;s a < guest. Protected by copyright. FIG. 4 Case 1. Trigeminal root: infiltration along the FIG. 5 Case 1. Trigeminal root: tangled whorls of course of nerve fibres and in walls of blood vessels. large calibre nerve fibres, probably derivedfrom motor Thioflavin T (Mercury vapour lamp, exciter filter root. Glees-Marsland silver impregnation, x 120. Schott UGJ, barrier filter Schott -50), x 200. meninal ganglion were remarkably well preserved in traumatic neuromas of the nerve roots (Fig. 5).
Load more

Recommended publications
  • Neuropathy, Radiculopathy & Myelopathy
    Neuropathy, Radiculopathy & Myelopathy Jean D. Francois, MD Neurology & Neurophysiology Purpose and Objectives PURPOSE Avoid Confusing Certain Key Neurologic Concepts OBJECTIVES • Objective 1: Define & Identify certain types of Neuropathies • Objective 2: Define & Identify Radiculopathy & its causes • Objective 3: Define & Identify Myelopathy FINANCIAL NONE DISCLOSURE Basics What is Neuropathy? • The term 'neuropathy' is used to describe a problem with the nerves, usually the 'peripheral nerves' as opposed to the 'central nervous system' (the brain and spinal cord). It refers to Peripheral neuropathy • It covers a wide area and many nerves, but the problem it causes depends on the type of nerves that are affected: • Sensory nerves (the nerves that control sensation>skin) causing cause tingling, pain, numbness, or weakness in the feet and hands • Motor nerves (the nerves that allow power and movement>muscles) causing weakness in the feet and hands • Autonomic nerves (the nerves that control the systems of the body eg gut, bladder>internal organs) causing changes in the heart rate and blood pressure or sweating • It May produce Numbness, tingling,(loss of sensation) along with weakness. It can also cause pain. • It can affect a single nerve (mononeuropathy) or multiple nerves (polyneuropathy) Neuropathy • Symptoms usually start in the longest nerves in the body: Feet & later on the hands (“Stocking-glove” pattern) • Symptoms usually spread slowly and evenly up the legs and arms. Other body parts may also be affected. • Peripheral Neuropathy can affect people of any age. But mostly people over age 55 • CAUSES: Neuropathy has a variety of forms and causes. (an injury systemic illness, an infection, an inherited disorder) some of the causes are still unknown.
    [Show full text]
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • Hereditary Spastic Paraplegia
    8 Hereditary Spastic Paraplegia Notes and questions Hereditary Spastic Paraplegia What is Hereditary Spastic Paraplegia? Hereditary Spastic Paraplegia (HSP) is a medical term for a condition that affects muscle function. The terms spastic and paraplegia comes from several words in Greek: • ‘spastic’ means afflicted with spasms (an alteration in muscle tone that results in affected movements) • ‘paraplegia’ meaning an impairment in motor or sensory function of the lower extremities (from the hips down) What are the signs and symptoms of HSP? Muscular spasticity • Individuals with HSP commonly will have lower extremity weakness, spasticity, and muscle stiffness. • This can cause difficulty with walking or a “scissoring” gait. We are grateful to an anonymous donor for making a kind and Other common signs or symptoms include: generous donation to the Neuromuscular and Neurometabolic Centre. • urinary urgency • overactive or over responsive “brisk” reflexes © Hamilton Health Sciences, 2019 PD 9983 – 01/2019 Dpc/pted/HereditarySpasticParaplegia-trh.docx dt/January 15, 2019 ____________________________________________________________________________ 2 7 Hereditary Spastic Paraplegia Hereditary Spastic Paraplegia HSP is usually a chronic or life-long disease that affects If you have any questions about DM1, please speak with your people in different ways. doctor, genetic counsellor, or nurse at the Neuromuscular and Neurometabolic Centre. HSP can be classified as either “Uncomplicated HSP” or “Complicated HSP”. Notes and questions Types of Hereditary Spastic Paraplegia 1. Uncomplicated HSP: • Individuals often experience difficulty walking as the first symptom. • Onset of symptoms can begin at any age, from early childhood through late adulthood. • Symptoms may be non-progressive, or they may worsen slowly over many years.
    [Show full text]
  • Peripheral Neuropathy
    Peripheral Neuropathy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Peripheral Neuropathy What is peripheral neuropathy? n estimated 20 million people in A the United States have some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system — the vast communications network that transmits information between the central nervous system (the brain and spinal cord) and every other part of the body. (Neuropathy means nerve disease or damage.) Symptoms can range from numbness or tingling, to pricking sensations (paresthesia), or muscle weakness. Areas of the body may become abnormally sensitive leading to an exaggeratedly intense or distorted experience of touch (allodynia). In such cases, pain may occur in response to a stimulus that does not normally provoke pain. Severe symptoms may include burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Damage to nerves that supply internal organs may impair digestion, sweating, sexual function, and urination. In the most extreme cases, breathing may become difficult, or organ failure may occur. Peripheral nerves send sensory information back to the brain and spinal cord, such as a message that the feet are cold. Peripheral 1 nerves also carry signals from the brain and spinal cord to the muscles to generate movement. Damage to the peripheral nervous system interferes with these vital connections. Like static on a telephone line, peripheral neuropathy distorts and sometimes interrupts messages between the brain and spinal cord and the rest of the body. Peripheral neuropathies can present in a variety of forms and follow different patterns.
    [Show full text]
  • General Approach to Peripheral Nerve Disorders
    Review Article Address correspondence to Dr James A. Russell, General Approach to Lahey Hospital and Medical Center, Department of Neurology, 41 Mall Rd, Peripheral Nerve Burlington, MA 01805, [email protected]. Relationship Disclosure: Disorders Dr Russell has served as a consultant for W2O Group, receives publishing royalties James A. Russell, DO, FAAN from McGraw-Hill Education, and has received personal compensation for medicolegal ABSTRACT record review. Unlabeled Use of Purpose of Review: This article provides a conceptual framework for the Products/Investigational evaluation of patients with suspected polyneuropathy to enhance the clinician’s Use Disclosure: ability to localize and confirm peripheral nervous system pathology and, when Dr Russell reports no disclosure. possible, identify an etiologic diagnosis through use of rational clinical and judicious * 2017 American Academy testing strategies. of Neurology. Recent Findings: Although these strategies are largely time-honored, recent insights pertaining to the pathophysiology of certain immune-mediated neuropa- thies and to evolving genetic testing strategies may modify the way that select causes of neuropathy are conceptualized, evaluated, and managed. Summary: The strategies suggested in this article are intended to facilitate accurate bedside diagnosis in patients with suspected polyneuropathy and allow efficient and judicious use of supplementary testing and application of rational treatment when indicated. Continuum (Minneap Minn) 2017;23(5):1241–1262. INTRODUCTION
    [Show full text]
  • Small Fiber Neuropathy in Patients Meeting Diagnostic Criteria For
    olog eur ica N l D f i o s l o a r n d r e u r s o J Levine, et al., J Neurol Disord 2016, 4:7 Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000305 ISSN: 2329-6895 Research Article Open Access Small Fiber Neuropathy in Patients Meeting Diagnostic Criteria for Fibromyalgia Todd D Levine1*, David S Saperstein1, Aidan Levine1, Kevin Hackshaw2 and Victoria Lawson2 1Phoenix Neurological Associates, 5090 N, 40th Street, Suite 250, Phoenix, AZ 85018, USA 2Division of Neuromuscular Diseases, Department of Neurology, The Ohio State Wexner Medical Center, 395 W. 12th Ave, 7th Floor, Columbus, OH 43210, USA *Corresponding author: Todd D Levine, Phoenix Neurological Associates, LTD. 5090 N 40th Street, Suite # 250, Phoenix, AZ 85018, USA, Tel: 6022583354; Fax: 6022583368; E-mail: [email protected] Rec date: Sep 21, 2016; Acc date: Oct 06, 2016; Pub date: Oct 11, 2016 Copyright: © 2016 Levine TD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: The cause for fibromyalgia (FM) is unknown and diagnostic criteria can be nonspecific. Many patients with FM have nonspecific sensory symptoms consistent with a neuropathic process. Previous studies have shown that a significant percentage of patients diagnosed with FM have small fiber neuropathy (SFN) based on decreased intraepidermal nerve fiber density (IENFD) on according to punch skin biopsy testing. The purpose of this study was to demonstrate that punch skin biopsy testing is an effective way to identify SFN and its underlying causes in patients previously diagnosed with FM.
    [Show full text]
  • Pharmacologic Management of Chronic Neuropathic Pain Review of the Canadian Pain Society Consensus Statement
    Clinical Review Pharmacologic management of chronic neuropathic pain Review of the Canadian Pain Society consensus statement Alex Mu MD FRCPC Erica Weinberg MD Dwight E. Moulin MD PhD Hance Clarke MD PhD FRCPC Abstract Objective To provide family physicians with EDITOR’S KEY POINTS a practical clinical summary of the Canadian • Gabapentinoids and tricyclic antidepressants play an important role in Pain Society (CPS) revised consensus first-line management of neuropathic pain (NeP). Evidence published statement on the pharmacologic management since the 2007 Canadian Pain Society consensus statement on treatment of neuropathic pain. of NeP shows that serotonin-norepinephrine reuptake inhibitors should now also be among the first-line agents. Quality of evidence A multidisciplinary • Tramadol and opioids are considered second-line treatments owing to their interest group within the CPS conducted a increased complexity of follow-up and monitoring, plus their potential for systematic review of the literature on the adverse side effects, medical complications, and abuse. Cannabinoids are current treatments of neuropathic pain in currently recommended as third-line agents, as sufficient-quality studies are drafting the revised consensus statement. currently lacking. Recommended fourth-line treatments include methadone, anticonvulsants with lesser evidence of efficacy (eg, lamotrigine, lacosamide), tapentadol, and botulinum toxin. There is some support for analgesic Main message Gabapentinoids, tricyclic combinations in selected NeP conditions. antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents • Many of these pharmacologic treatments are off-label for pain or for treating neuropathic pain. Tramadol and on-label for specific pain conditions, and these issues should be clearly other opioids are recommended as second- conveyed and documented.
    [Show full text]
  • Peripheral Neuropathy Is a Common Neurological Disorder Resulting from Damage/Degeneration of the Peripheral Nerves (I.E
    What is Peripheral Neuropathy? Peripheral Neuropathy is a common neurological disorder resulting from damage/degeneration of the peripheral nerves (i.e. the nerves that leave the spinal cord and brain and travel to the limbs, trunk, and organs). Neuropathy can affect one (mononeuropathy) or multiple (polyneuropathy) nerves. It may be caused by diseases of the nerves or as the result of systemic illnesses. Many neuropathies have well-defined causes such as diabetes, uremia/kidney disease, AIDS, thyroid disease, or nutritional deficiencies. In fact, diabetes is one of the most common causes of peripheral neuropathy. Some neuropathies are hereditary while others can result from exposure to toxins such as heavy metals, drugs, or alcohol. Other forms of neuropathy can result from direct pressure on nerves due to entrapment, trauma, penetrating injuries, contusions, fracture, or dislocated bones. Pressure involving the superficial nerves can result from prolonged use of crutches or staying in one position for too long. Pressure from a tumor can occasionally cause loss of function in a nerve. One common example of entrapment neuropathy is carpal tunnel syndrome. Although the causes of peripheral neuropathy are diverse, they produce common symptoms including weakness, numbness, paresthesias (abnormal sensations such as burning, pins/needles sensations, or tingling) and pain in the arms, hands, legs and/or feet. The most common form of neuropathy tends to involve the toes, feet, and/or lower legs and usually is symmetrical. About 85% of “garden-variety” neuropathies have no specific identifiable (i.e. reversible) cause. However, 15% of cases have an identifiable cause. It is these cases which can be treated, halted, or reversed.
    [Show full text]
  • Distinguishing Radiculopathies from Mononeuropathies
    CURRICULUM, INSTRUCTION, AND PEDAGOGY published: 13 July 2016 doi: 10.3389/fneur.2016.00111 Distinguishing Radiculopathies from mononeuropathies Jennifer Robblee and Hans Katzberg* Division of Neurology, University Health Network (UHN), University of Toronto, Toronto, ON, Canada Identifying “where is the lesion” is particularly important in the approach to the patient with focal dysfunction where a peripheral localization is suspected. This article outlines a methodical approach to the neuromuscular patient in distinguishing focal neuropathies versus radiculopathies, both of which are common presentations to the neurology clinic. This approach begins with evaluation of the sensory examination to determine whether there are irritative or negative sensory signs in a peripheral nerve or dermatomal distri- bution. This is followed by evaluation of deep tendon reflexes to evaluate if differential hyporeflexia can assist in the two localizations. Finally, identification of weak muscle groups unique to a nerve or myotomal pattern in the proximal and distal extremities can most reliably assist in a precise localization. The article concludes with an application of the described method to the common scenario of distinguishing radial neuropathy versus C7 radiculopathy in the setting of a wrist drop and provides additional examples for self-evaluation and reference. Edited by: Keywords: radiculopathy, focal neuropathy, mononeuropathy, neuromuscular, nerve root Adolfo Ramirez-Zamora, Albany Medical College, USA Reviewed by: INTRODUCTION Ignacio Jose Previgliano, Maimonides University Although nerve conduction studies (NCS) and electromyography (EMG) are standard tests in the School of Medicine, Argentina evaluation of focal peripheral neuropathies (1), newer techniques, including peripheral nerve ultra- Robert Jerome Frysztak, sound and MRI neurography, have started to gain acceptance (2).
    [Show full text]
  • Neuropathic Pain a Management Update Milana Votrubec Ian Thong
    Pain Neuropathic pain A management update Milana Votrubec Ian Thong Background Neuropathic pain is defined as ‘pain arising as a Neuropathic pain is described as burning, painful, cold or direct consequence of a lesion or disease affecting the electric shocks and may be associated with tingling, pins and somatosensory system’.1 This article will focus on the needles, numbness or itching. detection and management of diabetic polyneuropathy, Objective postherpetic neuralgia, trigeminal neuralgia and chronic This article summaries the diagnosis and management of four regional pain syndrome (CRPS). Importantly, disc disease common neuropathic pain presentations. and trauma can cause neuropathic pain, however these are Discussion beyond the scope of this article. A validated diagnostic screening tool can help identify patients with neuropathic pain. A systematic approach to A high index of suspicion is required for the diagnosis of neuropathic clinical assessment and investigation will clarify the diagnosis. pain as it can develop slowly over time. If neuropathic pain is suspected, Good glycaemic control is important in the prevention and a validated diagnostic screening tool such as the Leeds Assessment of management of diabetic polyneuropathy; management options Neuropathic Symptoms and Signs (LANSS), the Self reported LANSS include antidepressants, gabapentinoids and controlled release (S-LANSS), the Neuropathic Pain Questionnaire (NPQ), the Douleur opioids. Pain that lasts for more than 3 months after the onset Neuropathique en 4 (DN 4)
    [Show full text]
  • The Voice of the Patient: Neuropathic Pain Associated with Peripheral
    The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative Neuropathic Pain Associated with Peripheral Neuropathy Public Meeting: June 10, 2016 Report Date: February 2017 Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA) Table of Contents Introduction .............................................................................................................................. 3 Meeting overview ......................................................................................................................................... 3 Report overview and key themes ................................................................................................................. 4 Topic 1: Disease Symptoms and Daily Impacts That Matter Most to Patients .............................. 5 Perspectives on most significant symptoms ................................................................................................. 6 Overall impact of neuropathic pain associated with peripheral neuropathy on daily life ........................... 8 Topic 2: Patient Perspectives on Treatments for Neuropathic Pain Associated with Peripheral Neuropathy ............................................................................................................................... 9 Perspectives on current treatments ............................................................................................................. 9 Perspectives
    [Show full text]
  • Use of Methadone for the Treatment of Diabetic Neuropathy
    Reviews/Commentaries/ADA Statements COMMENTARY Use of Methadone for the Treatment of Diabetic Neuropathy LEWIS HAYS, MD, MPH MICHELLE DORAN, APRN, BC-PCM property, methadone, in theory, appears COLEEN REID, MD KARYN GEARY, APRN, BC-PCM to be the ideal opioid for neuropathic pain and may account for the demonstration that the need for opioid escalation was significantly less in patients treated for pain with methadone than in those Editor’s comment: This is the second Commentary of those that will appear from time to time describing treated with morphine (7,9). treatments that may not have been validated by appropriate clinical trials but seem to be effective in 2). Inhibition of the reuptake of nor- diabetic patients based on small studies and/or extensive clinical experience. This one describes effective epinephrine and serotonin. Facilitates im- opioid treatment for those diabetic patients failing nonopioid therapies for painful neuropathy. proved analgesia in neuropathic pain. Diabetes Care 28:485–487, 2005 Tricyclic antidepressants have traditionally been used to accomplish this task (2,10). 3). Trimodal metabolism/excretion. Metabolism in the liver via the cyto- ethadone, a schedule II opioid, to be more opioid responsive than those chrome P-450 system, fecal, and, to a was developed in Germany in the with pain from central nervous system le- lesser extent, renal excretion (other opi- M 1940s as a spasmolytic and was sions (5). Of the more than 2 million oids are excreted renally) (1). not used as an analgesic agent until many Americans affected by chronic neuro- 4). No active metabolites. This de- years later.
    [Show full text]